Migraine with brainstem aura is a kind of migraine where the warning signs (called aura) come from the brainstem—the deep part of the brain that helps control balance, hearing, eye movements, speech, and alertness. People get short-lasting, fully reversible symptoms like slurred speech, vertigo (a spinning feeling), ringing in the ears, double vision, poor coordination, or a brief drop in alertness. After the aura, a migraine headache often follows. There is no muscle weakness in this type; if weakness occurs, it is a different migraine type. These features and the formal diagnostic rules come from the International Classification of Headache Disorders, 3rd edition (ICHD-3). ICHD-3+1

Migraine with brainstem aura is a migraine that begins with warning symptoms coming from the brainstem—such as vertigo, slurred speech, ringing in the ears, double vision, poor coordination, reduced hearing, or brief reduced alertness—followed by a migraine headache. The aura symptoms are fully reversible and there is no limb weakness (if there is motor weakness, that’s a different diagnosis—hemiplegic migraine). Doctors diagnose it using the International Classification of Headache Disorders (ICHD-3) criteria, which list the specific brainstem symptoms and exclude motor and retinal symptoms. Previously used terms include basilar artery migraine and basilar-type migraine. ICHD-3+2ICHD-3+2

Doctors now prefer the name “migraine with brainstem aura” because earlier names suggested the basilar artery itself was the main cause. Research shows the artery is usually not directly at fault; the symptoms are due to migraine mechanisms involving brain networks. ICHD-3+1

Other names

Older or alternative terms include: basilar migraine, basilar-type migraine, and basilar artery migraine. All of these now fit under migraine with brainstem aura in ICHD-3. Using the current name helps keep diagnosis and research consistent. ICHD-3

Doctors diagnose this disorder when a person has migraine attacks that meet the usual migraine with aura rules and the aura clearly starts from the brainstem. The aura must include at least two brainstem symptoms (picked from: slurred speech, vertigo, ringing in the ears, reduced hearing, double vision, unsteady walking not due to numb feet, or a temporarily lowered level of consciousness) and must not include muscle weakness or retinal (eye-only) aura. Every symptom must fully go away. ICHD-3

Typical aura timing still applies: aura symptoms generally build over several minutes and last 5–60 minutes. The headache commonly follows. ICHD-3+2American Migraine Foundation+2 This is a rare subtype. It likely occurs in a small fraction of people with migraine and in a minority of those with aura. Estimates vary, but several clinical sources agree it is uncommon compared with other migraine forms. Medlink+1

Past theories focused on the basilar artery narrowing. Modern science points instead to migraine brain network changes (like cortical spreading depression and brainstem sensitivity) that can produce the distinctive brainstem symptoms. That is why guidelines moved from “basilar artery migraine” to “migraine with brainstem aura.” PMC

---

Types

ICHD-3 lists one formal category: migraine with brainstem aura. In clinic notes, doctors may describe presentations by the most prominent aura symptom, for example:

1. Vertigo-dominant brainstem aura – spinning sensation leads the attack, sometimes with nausea and imbalance. NCBI

2. Auditory-dominant brainstem aura – loud ringing (tinnitus) or reduced hearing is most noticeable. ICHD-3

3. Ocular-motor/diplopia-dominant aura – double vision or trouble coordinating eye movements. ICHD-3

4. Speech/alertness aura – slurred speech or a brief drop in alertness (not loss of consciousness from other causes), then recovery. ICHD-3

These “types” are descriptive patterns, not separate official diagnoses. The official diagnosis stays migraine with brainstem aura. ICHD-3

---

Causes and Triggers

We do not know one single cause. Most people have a migraine tendency and then attacks are triggered. Here are common triggers and risk factors in plain English:

1. Genetic tendency – migraine often runs in families; this sets the stage for aura. NCBI

2. Hormone shifts – periods, perimenopause, or hormonal contraceptive changes can set off attacks. American Headache Society

3. Stress – emotional stress can trigger the brain networks that start a migraine. American Headache Society

4. Too little sleep or irregular sleep – the brain becomes more sensitive. American Headache Society

5. Missed meals or low blood sugar – energy dips may start the aura. American Headache Society

6. Dehydration – low body water can trigger headaches and vertigo symptoms. American Headache Society

7. Bright or flickering lights – visual stress can precipitate aura. American Headache Society

8. Loud noise – sound sensitivity can act as a trigger. American Headache Society

9. Strong smells (perfumes, chemicals) – sensory overload can trigger attacks. American Headache Society

10. Alcohol (especially red wine) – common migraine trigger. American Headache Society

11. Caffeine change – either too much or sudden withdrawal can set off attacks. American Headache Society

12. Weather changes – pressure or temperature swings can be triggers. American Headache Society

13. Neck strain or prolonged posture – can make brainstem symptoms more likely during an attack. American Headache Society

14. Intense exercise without preparation – occasionally triggers aura. American Headache Society

15. Certain medicines (some vasodilators, some hormones) – can be associated with attacks in sensitive people; always discuss changes with a clinician. American Headache Society

16. High altitude or motion – can provoke vertigo-dominant aura. American Headache Society

17. Illness with fever – lowers the brain’s threshold. American Headache Society

18. Screen time without breaks – visual strain may bring on aura. American Headache Society

19. Dietary triggers (for some people): aged cheeses, processed meats, certain additives. Triggers vary widely person to person. American Headache Society

20. Menstruation-linked attacks – timing around the period is a frequent pattern. American Headache Society

(These triggers are well-described in educational resources for migraine with aura; exact triggers vary by individual.) American Migraine Foundation+1

---

Symptoms

1. Vertigo – a strong spinning or rocking feeling that can make standing or walking hard; it is fully reversible during the aura phase. ICHD-3+1

2. Dysarthria (slurred speech) – speech sounds thick or slow; this clears as the aura ends. ICHD-3

3. Tinnitus (ringing in the ears) – buzzing or ringing in one or both ears that fades. ICHD-3

4. Hypacusis (reduced hearing) – sounds seem muffled for a short time; then hearing returns to normal. ICHD-3

5. Diplopia (double vision) – seeing two images or crossed vision that resolves. ICHD-3

6. Ataxia (unsteady coordination) – clumsy steps or swaying without numb feet; balance normalizes afterward. ICHD-3

7. Decreased alertness – brief drowsiness or confusion; people recover baseline awareness. ICHD-3

8. Typical aura symptoms – shimmering lights, zigzags, or blind spots (visual aura) sometimes occur along with brainstem aura. American Migraine Foundation+1

9. Nausea – upset stomach is common when the headache follows the aura. StatPearls

10. Photophobia – bright light hurts during the attack. StatPearls

11. Phonophobia – ordinary sounds feel too loud during the attack. StatPearls

12. Occipital or whole-head pain – headache may start at the back or spread; intensity varies. StatPearls

13. Neck discomfort – neck tightness can accompany the headache phase. StatPearls

14. Paresthesia – tingling in face or hands may co-occur as part of aura. American Migraine Foundation

15. Speech/language difficulty – trouble finding words or speaking clearly (distinct from slurred speech) may appear with aura and then resolve. American Migraine Foundation

---

Diagnostic Tests

Doctors mainly use a careful history and neurologic exam to diagnose migraine with brainstem aura using ICHD-3 rules. Tests are chosen to rule out other serious causes (like stroke/TIA, seizures, inner-ear disease) when the story is not classic, when symptoms are new, or when red flags are present. ICHD-3+2ICHD-3+2

A) Physical exam (how you are checked in the clinic)

1. Vital signs and general exam – checking blood pressure, pulse, temperature, and hydration to spot other causes of dizziness or headache. StatPearls

2. Full neurologic exam – strength, sensation, reflexes, cranial nerves, and coordination to confirm that deficits are temporary and reversible. NCBI

3. Gait and balance assessment – observing standing, walking, and turning to document ataxia during the aura and recovery after. ICHD-3

4. Eye movement exam – checking for double vision and how the eyes track; this helps separate aura from eye muscle or nerve disease. ICHD-3

5. Ear and hearing screen – bedside hearing checks to corroborate tinnitus or transient hearing reduction. ICHD-3

B) Manual bedside tests (simple office tests)

6. Romberg test – standing with feet together, then eyes closed, to look for balance instability from brainstem/vestibular involvement. NCBI

7. Tandem gait – heel-to-toe walking to expose subtle ataxia. NCBI

8. Finger-to-nose and heel-to-shin – coordination tests to document cerebellar signs during aura. NCBI

9. Head-impulse test – quick head turns while fixing gaze; helps tell central vertigo (brainstem) from inner-ear causes like vestibular neuritis or BPPV. (Used to exclude other diagnoses.) ICHD-3

10. Dix-Hallpike maneuver – positions that provoke positional vertigo; a positive test points toward BPPV (an inner-ear disorder) rather than migraine aura. (Used differentially.) ICHD-3

C) Laboratory and pathological tests (used selectively)

11. Basic metabolic panel and glucose – looks for low sugar or electrolyte problems that can mimic aura or cause dizziness. StatPearls

12. Complete blood count (CBC) – checks for anemia or infection that can worsen headache or vertigo. StatPearls

13. Thyroid-stimulating hormone (TSH) – thyroid problems can present with headache or dizziness; this is checked when history suggests it. StatPearls

14. Vitamin B12 – severe deficiency can cause neurologic symptoms; tested if risk factors present. StatPearls

15. ESR/CRP – inflammation markers; in older adults with new headache they help screen for disorders like vasculitis. StatPearls

D) Electrodiagnostic studies (to rule out other conditions)

16. EEG – brain-wave test used when episodes include altered consciousness or when seizures are a concern; normal between attacks supports migraine rather than epilepsy. NCBI

17. Audiometry – formal hearing test when hypacusis or tinnitus persists or is unusual, to separate migraine aura from ear disease. NCBI

18. ECG – heart rhythm test when fainting or palpitations are in the story, to ensure symptoms are not cardiac. (Used case-by-case.) StatPearls

E) Imaging tests (to exclude dangerous causes)

19. MRI brain (with attention to posterior fossa) ± MRA – the key scan to rule out stroke, structural brainstem/cerebellar disease, or vascular problems when red flags exist or the pattern is new. NCBI

20. CT head or CTA head/neck – used in emergency settings when MRI is not available or urgent bleeding/stroke must be excluded. Choice depends on scenario. NCBI

(Your clinician decides which tests are necessary. Many people with a typical, repeated pattern and a normal exam may not need extensive testing.) NCBI

Non-pharmacological treatments (therapies & other measures)

1) Education & attack plan (written plan).
Knowing your diagnosis, typical triggers, red flags, and step-by-step actions improves control and reduces emergency visits. Plans usually specify when to use non-drug strategies first, when to add medicines or devices, and when to seek urgent care, aligned with modern acute-care principles from headache societies. PMC+1

2) Regular sleep (consistent schedule).
Keep the same sleep/wake times daily, including weekends. Poor or irregular sleep is a common trigger; steady sleep supports brainstem networks that modulate pain and aura spread, and is a standard preventive lifestyle recommendation in headache education resources. American Headache Society

3) Hydration & regular meals.
Dehydration and long gaps without food can trigger attacks. Routine water intake and balanced meals stabilize homeostasis and reduce physiologic stressors implicated in migraine threshold. Lifestyle guidance from headache organizations prioritizes these basics. American Headache Society

4) Caffeine management.
Limit daily caffeine and keep timing consistent; both excessive use and withdrawal can trigger migraine. A moderate routine (or tapering if over-using) helps avoid rebound. This is a frequent practical recommendation in migraine self-management guides. American Headache Society

5) Aerobic exercise (gradual, regular).
Moderate aerobic activity 3–5 times weekly can reduce attack frequency by affecting cortical excitability and stress pathways. Exercise is broadly recommended in preventive migraine programs and supported by clinical guidance as part of lifestyle therapy. American Headache Society

6) Trigger diary & pattern recognition.
Use a simple diary (sleep, stress, menses, foods, weather) to identify personal triggers and early aura signals (e.g., vertigo or diplopia). Pattern recognition helps you deploy acute therapy earlier and adjust preventives. This is a standard education step in headache care. American Headache Society

7) Stress-reduction skills (relaxation training).
Breathing, progressive muscle relaxation, guided imagery, and similar techniques reduce sympathetic arousal that can lower the threshold for attacks and brainstem-mediated aura. Relaxation skills have long been part of behavioral headache management. American Headache Society

8) Cognitive-behavioral therapy (CBT).
CBT addresses pain behaviors, fear of attacks, and stress reactivity, improving disability and treatment adherence. Behavioral programs are routinely recommended alongside medical therapy for migraine. American Headache Society

9) Biofeedback.
Thermal or EMG biofeedback trains physiologic control (e.g., hand warming, muscle relaxation), with evidence for fewer migraine days in many patients. It is a classic non-drug therapy within headache behavioral medicine. American Headache Society

10) Mindfulness-based strategies.
Mindfulness can dampen pain catastrophizing and improve coping with aura sensations (vertigo, tinnitus), supporting overall quality of life in migraine programs. It is commonly included in multimodal non-drug plans. American Headache Society

11) Vestibular rehabilitation (for prominent vertigo).
When vertigo is a dominant symptom during or between attacks, targeted vestibular therapy can improve balance, reduce motion sensitivity, and aid function; clinicians use it case-by-case in brainstem-aura phenotypes with vestibular features. PMC

12) Neuromodulation: external trigeminal nerve stimulation (Cefaly).
A forehead device (eTNS) delivers gentle impulses and is FDA-cleared for migraine prevention and acute relief. It offers a drug-free option and is supported by clinical use and device guidance. American Migraine Foundation+1

13) Neuromodulation: non-invasive vagus nerve stimulation (gammaCore).
A handheld stimulator at the neck provides nVNS and is FDA-cleared for acute migraine treatment (and some preventive uses). Trials suggest meaningful pain relief for selected patients who prefer non-drug options. FDA Access Data+1

14) Neuromodulation: remote electrical neuromodulation (Nerivio).
An upper-arm wearable controlled by a smartphone uses conditioned pain modulation and is FDA De Novo/cleared for acute and preventive treatment in patients ≥8 years. It avoids vasoconstriction—useful when triptans/ergots are contraindicated. bluecrossnc.com+1

15) Blue-light and screen management.
Dimming screens, using breaks, or filtered lighting can reduce photophobia burden during and between attacks. Patient-education materials commonly include environmental adjustments to reduce sensory load. American Headache Society

16) Migraine-friendly work/school accommodations.
Flexible breaks, reduced visual strain, and safe rest space can lower attack impact; practical guidance from headache groups emphasizes workplace/school plans to sustain function. American Headache Society

17) Menstrual planning (if applicable).
For predictable menstrual-linked worsening, non-drug measures (sleep regularity, hydration, heat therapy) plus device use at prodrome may reduce attack severity; formal drug plans can then be layered as needed. American Headache Society

18) Avoiding medication-overuse headache.
Limit simple analgesics to ≤14 days/month and combination agents to ≤9 days/month to prevent rebound. This principle underpins acute-care guidance and should be in every plan. PMC

19) Travel & motion strategies.
For motion-sensitive vertigo, sit over the vehicle axles, use stable visual horizons, and pre-plan breaks. Vestibular-focused tips are often advised when brainstem-aura vertigo predominates. PMC

20) Comorbidity care (anxiety, sleep apnea, etc.).
Treating co-existing problems lowers attack frequency and improves preventive response (e.g., CBT-I for insomnia; CPAP for apnea). Headache society resources stress comprehensive care. American Headache Society

---

Drug treatments

How to read this section: I list commonly used acute and preventive options that don’t cause vasoconstriction first (often preferred in brainstem aura), then note vasoconstrictive agents with current FDA label contraindications for “basilar/hemiplegic” migraine so you can avoid unsafe choices. Always individualize dosing and precautions with your clinician.

Acute—non-vasoconstrictive

1. Ubrogepant (Ubrelvy, oral).
   A CGRP receptor antagonist (“gepant”) for acute attacks. Usual dose 50–100 mg; a second dose ≥2 hours later; max 200 mg/24 h. No vasoconstriction; useful where triptans/ergots are contraindicated. Watch CYP3A4 interactions. FDA Access Data+1

2. Rimegepant (Nurtec ODT, oral disintegrating).
   For acute treatment and episodic prevention. Acute: 75 mg once per 24 h; avoid repeating within 48 h with potent P-gp inhibitors. Hypersensitivity reactions have been reported. No vasoconstriction. FDA Access Data+1

3. Lasmiditan (Reyvow, oral).
   A 5-HT1F “ditan” that acts centrally without vasoconstriction; can cause driving impairment for ≥8 hours—plan your day accordingly. Useful when triptans are labeled-contraindicated. FDA Access Data+1

4. NSAIDs (e.g., ibuprofen, aspirin, diclofenac).
   First-line in acute care plans. They reduce neurogenic inflammation and pain. Combine with an antiemetic if needed; limit monthly use to avoid medication-overuse headache. PMC

5. Antiemetics for severe nausea (e.g., metoclopramide or prochlorperazine in urgent care).
   These dopamine antagonists help nausea and can improve headache outcomes in emergency department protocols; clinicians use them with fluids and NSAIDs as needed. PMC

Preventive—first-line or migraine-specific

6. Topiramate (Topamax).
   Evidence-based preventive; typical target 100 mg/day (titrated). Can reduce aura frequency; counsel about paresthesia, cognitive slowing, and pregnancy risks. FDA-labeled for migraine prevention (≥12 y). FDA Access Data+1

7. Divalproex/Valproate (Depakote/ER).
   Effective prevention but contraindicated for migraine prevention in pregnancy and in women of child-bearing potential without effective contraception due to serious fetal risks; use carefully. FDA Access Data+1

8. Propranolol (Inderal LA).
   Classic beta-blocker preventive; useful in many patients. Dosing individualized; avoid in asthma and some conduction issues. FDA-labeled for migraine prophylaxis. FDA Access Data

9. Atogepant (Qulipta).
   Oral gepant for preventive therapy; daily dosing, updated warnings as of 2025 labeling. No vasoconstriction; consider drug interactions. FDA Access Data

10. Erenumab (Aimovig).
    Monthly CGRP-receptor monoclonal antibody injection; first-line per 2024 AHS position statement; monitor for constipation or hypertension. FDA Access Data+1

11. Fremanezumab (Ajovy).
    Monthly or quarterly CGRP-ligand mAb; option when oral preventives fail or are not tolerated; updated safety labeling in 2025. FDA Access Data+1

12. Galcanezumab (Emgality).
    Monthly CGRP-ligand mAb; widely used preventive with established dosing and self-injection instructions. FDA Access Data+1

13. Eptinezumab (Vyepti, IV q3 months).
    Clinic infusion every 3 months; rapid onset in some patients; dose 100 mg (some benefit from 300 mg). FDA Access Data

14. OnabotulinumtoxinA (Botox) for chronic migraine.
    For ≥15 headache days/month (≥8 migraine days), injected every 12 weeks in standardized sites; not a vasoconstrictor. nerivio.com

15. Amitriptyline (off-label for migraine).
    A tricyclic often used when poor sleep or mood symptoms coexist; evidence-supported in guidelines though not FDA-labeled for migraine. Dose titrated at night; watch anticholinergic effects. headachejournal.onlinelibrary.wiley.com

16. Venlafaxine (off-label).
    Serotonin-norepinephrine reuptake inhibitor used in some preventive plans, especially with comorbid anxiety/depression; evidence from practice guidance. headachejournal.onlinelibrary.wiley.com

17. Candesartan (off-label).
    An ARB with growing evidence for prevention and good tolerability; consider in patients with hypertension. NP Journal

18. Magnesium (acute IV in select urgent-care settings; oral preventive below).
    IV magnesium may help aura or headache in some settings, and oral forms are used preventively (see supplements). Use case-by-case. headachejournal.onlinelibrary.wiley.com

Agents to avoid in brainstem aura (vasoconstrictive—label contraindications apply)

19. Triptans (sumatriptan and class).
    Effective for many migraine types, but FDA labels list contraindication for hemiplegic or “basilar” migraine; discuss safer alternatives. FDA Access Data+1

20. Ergot derivatives (dihydroergotamine nasal/injectable).
    Also labeled as not for basilar/hemiplegic migraine; multiple formulations carry this restriction. FDA Access Data+1

Guideline context: The American Headache Society (AHS) 2021 acute-treatment consensus integrated the arrival of gepants/ditans, and the 2024 AHS position statement elevated CGRP-targeting preventives (mAbs/oral gepants) to first-line status alongside older options—useful when vasoconstrictive agents are contraindicated. headachejournal.onlinelibrary.wiley.com+1

---

Dietary molecular supplements

1. Magnesium (e.g., magnesium citrate or glycinate 300–400 mg elemental/day).
   Supports neuronal stability and may reduce aura propensity. Often recommended as a low-risk preventive option; diarrhea can limit dose; adjust form/dose individually. headachejournal.onlinelibrary.wiley.com

2. Riboflavin (Vitamin B2, ~400 mg/day).
   Improves mitochondrial energy metabolism; classic nutraceutical with supportive evidence in preventive guidelines; harmless yellow urine discoloration is common. headachejournal.onlinelibrary.wiley.com

3. Coenzyme Q10 (100–300 mg/day).
   Mitochondrial cofactor that may reduce migraine days; well-tolerated and often combined with magnesium or B2 in real-world plans. headachejournal.onlinelibrary.wiley.com

4. Vitamin D (dose per level, often 1000–2000 IU/day).
   Low vitamin D associates with higher migraine burden in some studies; repletion is reasonable when deficient per general medical practice. headachejournal.onlinelibrary.wiley.com

5. Melatonin (2–5 mg at bedtime).
   Can help sleep regularity and may reduce migraine frequency for some; useful when insomnia co-exists. headachejournal.onlinelibrary.wiley.com

6. Omega-3 fatty acids (EPA/DHA ~1–2 g/day).
   Anti-inflammatory effects may modestly lower attack frequency; choose quality-controlled products. headachejournal.onlinelibrary.wiley.com

7. Ginger (standardized extract with meals or at onset).
   Helpful for nausea and possibly headache intensity in some patients; integrates well with antiemetic plans. headachejournal.onlinelibrary.wiley.com

8. Alpha-lipoic acid (e.g., 600 mg/day).
   Antioxidant/mitochondrial cofactor sometimes used as adjunctive prevention; monitor for GI upset. headachejournal.onlinelibrary.wiley.com

9. Feverfew (standardized, caution with quality).
   Herbal with mixed evidence; if used, pick standardized preparations and stop before surgery; discuss risks/benefits first. headachejournal.onlinelibrary.wiley.com

10. Butterbur (not routinely recommended).
    Historical evidence exists, but hepatotoxic pyrrolizidine alkaloids are a concern; most experts no longer recommend routine use unless a PA-free product is verified—discuss carefully. headachejournal.onlinelibrary.wiley.com

---

Immunity-booster / regenerative / stem-cell” drugs

There are no FDA-approved “immunity-boosting,” regenerative, or stem-cell drugs for migraine prevention or for migraine with brainstem aura. Evidence-based, migraine-specific options are those above (e.g., CGRP-targeting mAbs/gepants, topiramate, beta-blockers, onabotulinumtoxinA). If you were considering investigational biologics, discuss clinical-trial options with a specialist; outside trials, such products should not be used. FDA Access Data+3PubMed+3FDA Access Data+3

---

Procedures/surgeries

1. OnabotulinumtoxinA injections (for chronic migraine).
   An office procedure every 12 weeks using standardized injection sites; reduces headache days by modulating peripheral/sensory inputs without vasoconstriction. FDA-approved for chronic migraine (≥15 headache days/month). nerivio.com

2. Non-invasive neuromodulation devices (Cefaly, gammaCore, Nerivio).
   Home-use devices (see above) provide procedural-type neuromodulation without surgery; they are FDA-cleared and can be used acutely and/or preventively depending on the device. American Migraine Foundation+2FDA Access Data+2

3. Occipital nerve stimulation / implanted stimulators (refractory cases).
   For highly refractory migraine, implantable stimulators have been tried in clinical studies; use is limited and typically research- or specialty-center-based. Not standard for brainstem aura. Medscape

4. Sphenopalatine ganglion procedures (investigational for migraine).
   Blocks/stimulation are studied but not standard for this subtype; consider only in research/specialist contexts after exhausting evidence-based options. Medscape

5. “Migraine surgery” (peripheral nerve decompression).
   The American Headache Society has cautioned against routine use of migraine surgery outside clinical trials due to limited high-quality evidence and potential harms; it’s not standard care for brainstem aura. FDA Access Data

---

Practical preventions

1. Same wake/sleep time every day.

2. Hydrate through the day.

3. Don’t skip meals.

4. Keep caffeine modest and consistent.

5. Gradual aerobic exercise most days.

6. Stress skills (breathing/relaxation).

7. Trigger diary and early-treatment plan.

8. Limit acute meds to avoid medication-overuse headache.

9. Prepare a travel/motion plan if vertigo-prone.

10. Manage comorbidities (sleep disorders, anxiety, depression) with your clinician. American Headache Society+1

---

When to see a doctor

Seek emergency care for a first or worst headache; new neurologic deficits; abrupt, persistent double vision; prolonged decreased consciousness; new asymmetric weakness; or stroke-like symptoms. For known brainstem-aura migraine, see your clinician promptly if attacks are more frequent, last longer, change character, or don’t respond to your acute plan—especially if you are only using over-the-counter medicines. Use non-vasoconstrictive options if you have brainstem aura; avoid triptans/ergots unless a specialist specifically advises otherwise. ICHD-3+1

---

What to eat & what to avoid

1. Eat regular, balanced meals (protein + complex carbs + healthy fat) to avoid glucose dips.

2. Hydrate steadily (water first).

3. Moderate caffeine (same amount, same time daily).

4. Consider magnesium-rich foods (nuts, legumes, greens).

5. Omega-3 sources (fatty fish, flax/walnuts).

6. Limit alcohol, especially red wine if it’s a personal trigger.

7. Watch additives (e.g., high-nitrite meats, excess MSG) only if they’re personal triggers.

8. Steady meal timing on busy days/travel.

9. Gentle ginger (tea/capsules) for nausea.

10. Keep a food-symptom diary to personalize triggers instead of following generic lists. American Headache Society

---

Frequently asked questions

1) Is “basilar artery migraine” the same as migraine with brainstem aura?
Yes. The modern ICHD-3 name is migraine with brainstem aura; older terms include “basilar artery migraine” and “basilar-type migraine.” ICHD-3

2) What symptoms count as brainstem aura?
Reversible symptoms such as dysarthria, vertigo, tinnitus, hypacusis, diplopia, ataxia (not from sensory loss), or decreased level of consciousness—without motor weakness. ICHD-3

3) How long does the aura last?
Each symptom typically lasts 5–60 minutes and is followed by headache, though timing varies. ICHD-3

4) Are triptans safe for brainstem aura?
US labels for triptans list contraindications for basilar/hemiplegic migraine; many clinicians avoid them and choose non-vasoconstrictive options instead. FDA Access Data

5) Are ergot drugs safe here?
No—dihydroergotamine labels say not for basilar/hemiplegic migraine. FDA Access Data

6) What are my acute options if triptans/ergots are off the table?
Gepants (ubrogepant, rimegepant), ditan (lasmiditan), NSAIDs, antiemetics, hydration, rest, and neuromodulation devices are common choices; personalize with your clinician. PMC+3FDA Access Data+3FDA Access Data+3

7) What about prevention?
Topiramate, propranolol, valproate (with strict pregnancy precautions), onabotulinumtoxinA for chronic migraine, and CGRP-targeting mAbs or atogepant are core options. FDA Access Data+3FDA Access Data+3FDA Access Data+3

8) Are CGRP-targeting therapies first-line now?
Yes—AHS 2024 states CGRP-targeting preventives can be first-line alongside older options. PubMed

9) Do supplements help?
Magnesium, riboflavin, CoQ10 and others can be useful adjuncts with good safety; discuss dosing and interactions. headachejournal.onlinelibrary.wiley.com

10) Do devices really work?
Cefaly (eTNS), gammaCore (nVNS), and Nerivio (REN) have FDA clearance and clinical support for selected patients who want medication-sparing options. American Migraine Foundation+2FDA Access Data+2

11) Is this the same as vestibular migraine?
They can overlap in vertigo features, but diagnostic rules differ; in brainstem aura, vertigo is part of a defined aura pattern and timing per ICHD-3. ICHD-3

12) Can kids or teens have this?
Diagnosis is stricter in children due to stroke mimics; pediatric treatment aligns with safety-first principles—specialist assessment is advised. (General guidance pages emphasize careful evaluation.) ICHD-3

13) What if attacks cluster around menstruation?
Use lifestyle tightening and consider device or gepant strategies at prodrome; clinicians may also tailor preventive plans for menstrual patterns. American Headache Society

14) How do I prevent medication-overuse headache?
Limit acute meds to recommended monthly maximums and use preventives if you need frequent treatment. PMC

15) What should my “go-bag” include?
Your written plan, a non-vasoconstrictive acute option (e.g., gepant or lasmiditan), antiemetic, hydration, eye mask/earplugs, and access to your device (if using), so you can treat early. PMC

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: October 19, 2025.